Corrigendum: Androgen insensitivity syndrome: preventive gonadectomy, 'pros' and 'cons' (Obesity and metabolism. 2024;21(1):85-91. doi: https://doi.org/10.14341/omet13024)
| Autor: | E. A. Starostina, N. V. Frolkova, S. M. Seidova, E. G. Przhiyalkovskaya, N. M. Platonova, E. A. Troshina |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Ожирение и метаболизм, Vol 21, Iss 2, Pp 172-173 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2071-8713 2306-5524 |
| DOI: | 10.14341/omet13159 |
| Popis: | A corrigendum on "Androgen insensitivity syndrome: preventive gonadectomy, "pros" and "cons"" (Obesity and metabolism by Еvgenia A. Starostina, Nadezhda V. Frolkova, Seidbike M. Seidova, Elena G. Przhiyalkovskaya, Nadezhda M. Platonova (2024). Obesity and metabolism. 2024;21(1):85-91. doi: https://doi.org/10.14341/omet13024On page 87 the sentence “In addition, testosterone preparations are used to treat infertility in patients with a mild form of STF [3]” was removed. Added paragraph “Birnbaum W et al. conducted a multicenter, double-blind, randomized, crossover study in three university medical centers and three specialized hospitals in Germany. In this study, patients aged 18-54 years with karyotype 46,XY, genetically confirmed CAIS, removed gonads, were treated with either estradiol drugs at a dose of 1.5 mg/day for 6 months, followed by a transition to testosterone 50 mg /day for 6 months (sequence A), or testosterone preparations 50 mg/day for 6 months, followed by a transition to estradiol 1.5 mg/day for 6 months (sequence B).In the study, testosterone was well tolerated and as safe as estrogen. The authors suggested that testosterone may be an alternative replacement therapy for CAIS, particularly for patients with reduced sexual function."A new source has been added in the reference list section under No. 30: “Birnbaum W, Marshall L, Werner R, et al. Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomized, double-dummy, double-blind crossover trial. Lancet Diabetes Endocrinol. 2018;6(10):771-780. doi:10.1016/S2213-8587(18)30197-9.”The authors regret the error. The original version of the article has been replaced. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|